bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
241 hedge funds and large institutions have $5.17B invested in bluebird bio in 2017 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 95 increasing their positions, 66 reducing their positions, and 19 closing their positions.
163% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 19
122% more call options, than puts
Call options by funds: $109M | Put options by funds: $49M
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
44% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 66
22% more capital invested
Capital invested by funds: $4.24B → $5.17B (+$938M)
15% more funds holding
Funds holding: 210 → 241 (+31)
0.3% less ownership
Funds ownership: 8.81% → 8.51% (-0.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$55.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$54.7M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$45.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$32M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$25.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$44.7M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$25.4M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$18.7M |
| 4 |
PC
PointState Capital
New York
|
-$15.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$14.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
251
Schroder Investment Management Group
London,
United Kingdom
| – | -$580K | -488 | Closed |
|
252
Marshall Wace
London,
United Kingdom
| – | -$448K | -380 | Closed |
|
|
PAM
253
Princeton Alpha Management
Princeton Junction,
New Jersey
| – | -$255K | -216 | Closed |
|
|
SCM
254
Sterling Capital Management
Charlotte,
North Carolina
| – | -$225K | -191 | Closed |
|
|
NFA
255
Nuveen Fund Advisors
Chicago,
Illinois
| – | -$205K | -174 | Closed |
|
|
CLOS
256
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| – | -$41K | -35 | Closed |
|
|
SCM
257
Segantii Capital Management
Hong Kong
| – | -$36K | -31 | Closed |
|
|
FAAS
258
First Allied Advisory Services
San Diego,
California
| – | -$217K | -30 | Closed |
|
|
AIM
259
Advantage Investment Management
Cedar Rapids,
Iowa
| – | -$1K | -1 | Closed |
|
BLUE Hedge Fund Activity: Q2 2017 in Review
241 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q2 2017, worth a combined $5.17B — up 22% from $4.24B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new BLUE positions and 19 closed out — a net gain of 31 holders — while 95 added to existing stakes and 66 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $55.9M. The largest seller was Franklin Resources, cutting an estimated $44.7M.
- 241 institutional investors held bluebird bio (BLUE) as of Q2 2017, up from 210 in Q1 2017.
- Funds reported $5.17B of bluebird bio stock for Q2 2017, up 22% quarter-over-quarter.
- 50 funds opened new bluebird bio positions in Q2 2017 and 19 closed out, a net change of +31 holders.
- The largest bluebird bio buyer in Q2 2017 was Wellington Management Group, an estimated $55.9M added.
- The largest bluebird bio seller in Q2 2017 was Franklin Resources, an estimated $44.7M sold.
Based on aggregated 13F filings for Q2 2017.